Aussie GM announces retirement

Posted 12 March 2024 PM

Chiesi Australia General Manager Chris Rossidis, who brought Australia's first medicinal cannabinoid product to Australia, is leaving the company to retire at the end of this month.

Rossidis was the driving force behind the registration and  PBS-listing of Epidyolex for the treatment seizures associated with Lennox-Gastaut syndrome or Dravet syndrome. Both are rare types of childhood-onset epilepsy, which cause patients to experience severe symptoms which include repeated and prolonged seizures. 

To see the whole article, please login